表紙
市場調查報告書

視黃酸受體伽馬:開發中產品分析

Retinoic Acid Receptor Gamma - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 557376
出版日期 內容資訊 英文 82 Pages
訂單完成後即時交付
價格
Back to Top
視黃酸受體伽馬:開發中產品分析 Retinoic Acid Receptor Gamma - Pipeline Review, H2 2019
出版日期: 2019年11月25日內容資訊: 英文 82 Pages
簡介

本報告提供以視黃酸受體伽馬為標的之治療藥開發平台現狀及最新更新之各開發階段比較分析,提供涵括了最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

視黃酸受體伽馬;概要

視黃酸受體伽馬;治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀
  • 企業開發中的產品

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • 3SBio Inc
  • Boehringer Ingelheim GmbH
  • Clementia Pharmaceuticals Inc
  • Galderma SA
  • Lee's Pharmaceutical Holdings Ltd
  • Phosphagenics Ltd
  • Promius Pharma LLC
  • Sol-Gel Technologies Ltd
  • Valeant Pharmaceuticals International Inc

藥物簡介

暫停中的產品

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1957TDB

Summary:

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) pipeline Target constitutes close to 19 molecules. Out of which approximately 19 molecules are developed by Companies. The latest report Retinoic Acid Receptor Gamma - Pipeline Review, H2 2019, outlays comprehensive information on the Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Retinoic acid receptor gamma (RARG) is a nuclear receptor that is encoded by the RARG gene. RARG bind as heterodimers to the target response elements in response to their ligands (all-trans or 9-cis retinoic acid) and regulate gene expression in various biological processes. In the absence or presence of hormone ligand, acts mainly as an activator of gene expression due to weak binding to co-repressors. It is required for limb bud development.

The molecules developed by companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 8, 2, 7 and 1 respectively. Report covers products from therapy areas Dermatology, Musculoskeletal Disorders, Oncology, Ophthalmology, Respiratory, Gastrointestinal, Genetic Disorders and Immunology which include indications Acne Vulgaris, Bronchopulmonary Dysplasia, Allergies, Autoimmune Disorders, Congenital Ichthyosis, Esophageal Cancer, Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Fibrosis, Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome), Head And Neck Cancer, Inflammatory Bowel Disease, Keratoconjunctivitis Sicca (Dry Eye), Multiple Hereditary Exostoses, Retinopathy Of Prematurity and Spondyloarthritis (Spondyloarthropathy).

Furthermore, this report also reviews key players involved in Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG)
  • The report reviews Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • List of Tables
  • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Overview
  • Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
  • Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Companies Involved in Therapeutics Development
    • 3SBio Inc
    • Advent Therapeutics Inc
    • Bausch Health Companies Inc
    • Boehringer Ingelheim International GmbH
    • Galderma SA
    • Ipsen SA
    • Lee's Pharmaceutical Holdings Ltd
    • Orphanix GmbH
    • Ortho Dermatologics Inc
    • Phosphagenics Ltd
    • Promius Pharma LLC
    • Sol-Gel Technologies Ltd
    • Sveikatal Inc
    • TherapyX Inc
  • Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Drug Profiles
    • (adapalene + benzoyl peroxide + clindamycin phosphate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (adapalene + clindamycin hydrochloride) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (benzoyl peroxide + tretinoin) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (benzoyl peroxide + tretinoin) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (clindamycin phosphate + tretinoin) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (TPX-6001 + tretinoin) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • alitretinoin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bexarotene + CD-1530 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • palovarotene - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize ROR-Gamma for Autoimmune and Allergic Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules 1 to Agonize Retinoic Acid Receptor Gamma for Musculoskeletal Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize RARG for Fibrosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize Retinoic Acid Receptor Gamma for Musculoskeletal Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tazarotene - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tazarotene - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tretinoin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tretinoin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • trifarotene - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vitamin A palmitate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vitamin A palmitate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Dormant Products
    • Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Discontinued Products
    • Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Product Development Milestones
  • Featured News & Press Releases
    • Oct 15, 2019: Bausch Health's Ortho Dermatologics business to present data on tazarotene at The Fall Clinical Dermatology Conference
    • Oct 15, 2019: Bausch Health's Ortho Dermatologics business to present data on acne drug tretinoin at The Fall Clinical Dermatology Conference
    • Oct 04, 2019: Galderma receives FDA approval for AKLIEF (trifarotene) cream, 0.005%, the first new retinoid molecule for the treatment of Acne in over 20 years
    • Aug 07, 2019: Ortho Dermatologics announces U.S. FDA filing acceptance for IDP-123 treatment for Acne Vulgaris in lotion form
    • Jul 09, 2019: GSK's Alitoc becoming salvation treatment for chronic hand eczema patients
    • Apr 15, 2019: Sol-Gel Technologies announces 50% enrollment in pivotal phase III TWIN Program for the treatment of Acne Vulgaris
    • Feb 28, 2019: Galderma Announces Publication of Pivotal Phase 3 PERFECT 1 and PERFECT 2 Clinical Trials of Trifarotene in Patients with Moderate Facial and Truncal Acne in the Journal of the American Academy of Dermatology
    • Feb 11, 2019: Clementia granted Rare Pediatric Disease Designation by FDA for Palovarotene for Fibrodysplasia Ossificans Progressiva
    • Dec 17, 2018: Sol-Gel Technologies initiates pivotal phase III clinical program of TWIN for the treatment of acne vulgaris
    • Oct 30, 2018: Bausch Health launches ALTRENO (tretinoin) Lotion, 0.05% in the United States
    • Oct 23, 2018: Clementia announces plan to submit a new drug application for Palovarotene for the treatment of FOP based on positive phase 2 results
    • Oct 15, 2018: Bausch Health's ortho dermatologics business to present on ALTRENO During The Fall Clinical Dermatology Conference
    • Oct 11, 2018: Bausch Health announces publication of pivotal phase 3 efficacy and safety data on ALTRENO (tretinoin) Lotion, 0.05%, in the journal of drugs in dermatology
    • Oct 02, 2018: Clementia initiates phase 1 clinical trial of palovarotene eye drop formulation in healthy volunteers
    • Sep 26, 2018: Clementia announces updated phase 2 part B data on Palovarotene for FOP
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by 3SBio Inc, H2 2019
  • Pipeline by Advent Therapeutics Inc, H2 2019
  • Pipeline by Bausch Health Companies Inc, H2 2019
  • Pipeline by Boehringer Ingelheim International GmbH, H2 2019
  • Pipeline by Galderma SA, H2 2019
  • Pipeline by Ipsen SA, H2 2019
  • Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2019
  • Pipeline by Orphanix GmbH, H2 2019
  • Pipeline by Ortho Dermatologics Inc, H2 2019
  • Pipeline by Phosphagenics Ltd, H2 2019
  • Pipeline by Promius Pharma LLC, H2 2019
  • Pipeline by Sol-Gel Technologies Ltd, H2 2019
  • Pipeline by Sveikatal Inc, H2 2019
  • Pipeline by TherapyX Inc, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top